The bearish institutional cluster is dominated by passive sellers (Morgan Stanley, Goldman Sachs, T. Rowe Price) reducing positions, while the sole buyer is a passive index fund (State Street). This suggests no strong active-manager conviction behind the stock. Monitor for any insider buying or a catalyst (earnings, pipeline update) before taking a position.
Executive Summary
BridgeBio Oncology Therapeutics (BBOT) saw a bearish institutional cluster in Q2 2026, with 4 sellers (including Morgan Stanley near-exiting and Goldman Sachs trimming 39%) outweighing 1 buyer (State Street doubling). Aggregate selling of ~$1.3M vs buying of $5.9M, but the selling is concentrated among active and mega-passive managers reducing exposure, while the sole buyer is a passive index fund. The cross-filing amplifier (inst-earnings + inst-offering) is present but does not override the weak standalone signal given the passive-heavy seller mix and poor track record.
Key Financial Metrics
Institutional Positions
Net institutional flow: $5.5M
▲ Buyers (1)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| State Street | DOUBLED | +358.1% | $7.9M | $5.9M |
▼ Sellers (4)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | NEAR_EXIT | -92.2% | $388.0K | -$362.4K |
| Goldman Sachs | TRIM | -39.1% | $1.5M | -$721.9K |
| T. Rowe Price | TRIM | -31.5% | $4.0K | -$1.6K |
| Td Asset Management | TRIM | -25.8% | $515.0K | -$189.7K |
Key Facts
- 4 institutional sellers vs 1 buyer in Q2 2026
- Morgan Stanley near-exited (-92.2% shares, $362K sold)
- Goldman Sachs trimmed 39.1% ($722K sold)
- T. Rowe Price trimmed 31.5% (small $1.6K position)
- Td Asset Management trimmed 25.8% ($190K sold)
- State Street doubled its position (+358.1%, $5.9M added) but is a passive index fund
- No open-market insider buying in the window
Financial Impact
Net institutional selling of ~$1.3M vs buying of $5.9M; aggregate seller holdings reduced by $1.28M while State Street added $5.9M. The selling is more concentrated among active/mega-passive managers reducing exposure.
Risk Factors
- Institutional selling may continue if fundamentals deteriorate
- Passive fund rebalancing could amplify selling pressure
- No insider buying to signal confidence from management
- Historical poor performance of BBOT calls suggests potential further downside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-BBOT-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | — |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | — |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | — |
Aug 11, 2026 10w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | — |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | — |
May 12, 2026 23w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | — |
Apr 21, 2026 26w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | — |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | — |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | — |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers